SynthesisFrontiers in pharmacology2022

The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China.

Mingjun Rui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.